New advancements, including automation, aim to fast-forward spatial biologySOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools...
Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca...
In combination with either atezolizumab or durvalumabMADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a...
Initial clinical data demonstrate a very high 85% overall response rate in patients with metastatic castrate-resistant prostate cancer. FORT LAUDERDALE,...
SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio’) (Nasdaq: TVGN), a clinical-stage biotech company,...
Hawaii Cancer Care partners with American Oncology Network to continue delivering quality cancer care to the community. American Oncology Network...
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical...
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results...
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from...
WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech...
Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development...
- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting,...
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to...
Study to assess new camptothecin-peptide conjugates for the treatment of sortilin-positive colorectal cancers Separate data to highlight activity of sudocetaxel...
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a...